Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Development of a serological microfluidic assay for the rapid detection of interferons in COVID-19 patients

FY 2021-22

Summary
Antibodies are a natural immune response developed by the body to protect against infection, but in some cases, individuals can develop autoantibodies that attack components of the individual's own body. As such, a dysfunctional immune response can result in an increased susceptibility to infection. In the case of COVID-19 patients, autoantibodies that attack immune system's hormones, like interferons, can result in life-threatening and critical COVID-19 infections. Therefore, the detection of these autoantibodies is critical in managing a patient's prognosis and monitoring for critical infections to protect those at the highest risk. Current testing methods are done in batch groupings and lack accessibility. We propose the use of a portable, instrument-free platform that can use direct patient blood samples to render a diagnostic readout. These kinds of technologies are analogous to the common pregnancy test lateral flow assay and allow for the monitoring of severe infection at the point-of-care, as well as provide a means of translating clinical assays into the hands of users.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
467005
Name
Shafique Houda
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of a serological microfluidic assay for the rapid detection of interferons in COVID-19 patients
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
3d Printing; Autoantibodies; Biomedical Engineering; Capillary Circuits; Chain Reaction; Covid-19; Elisa; Microbead Assays; Microfluidics; Serology
Abstract
Antibodies are a natural immune response developed by the body to protect against infection, but in some cases, individuals can develop autoantibodies that attack components of the individual's own body. As such, a dysfunctional immune response can result in an increased susceptibility to infection. In the case of COVID-19 patients, autoantibodies that attack immune system's hormones, like interferons, can result in life-threatening and critical COVID-19 infections. Therefore, the detection of these autoantibodies is critical in managing a patient's prognosis and monitoring for critical infections to protect those at the highest risk. Current testing methods are done in batch groupings and lack accessibility. We propose the use of a portable, instrument-free platform that can use direct patient blood samples to render a diagnostic readout. These kinds of technologies are analogous to the common pregnancy test lateral flow assay and allow for the monitoring of severe infection at the point-of-care, as well as provide a means of translating clinical assays into the hands of users.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Shafique, Houda
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~